# Safety and Immunogenicity of the Recombinant Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 18 Years and Older

> **NCT06904222** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Guangzhou Patronus Biotech Co., Ltd.** · enrollment: 90 (estimated)

## Conditions studied

- Respiratory Syncytial Virus Infection

## Interventions

- **BIOLOGICAL:** Low dose antigen of LYB005 without A01B adjuvant
- **BIOLOGICAL:** Low dose antigen of LYB005 with A01B adjuvant
- **BIOLOGICAL:** Middle dose antigen of LYB005 without A01B adjuvant
- **BIOLOGICAL:** Middle dose antigen of LYB005 with A01B adjuvant
- **BIOLOGICAL:** High dose antigen of LYB005 without A01B adjuvant
- **BIOLOGICAL:** High dose antigen of LYB005 with A01B adjuvant
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT06904222
- **Lead sponsor:** Guangzhou Patronus Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-04-15
- **Primary completion:** 2026-08
- **Final completion:** 2026-08
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06904222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06904222, "Safety and Immunogenicity of the Recombinant Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 18 Years and Older". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06904222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*